Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Enhancement of Macular Pigment Density by Oral Lutein Supplementation
Authors not listed
Insel Gruppe AG, University Hospital Bern · 2007
Abstract
The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2007). Enhancement of Macular Pigment Density by Oral Lutein Supplementation. <em>Insel Gruppe AG, University Hospital Bern</em>. https://clinicaltrials.gov/study/NCT00563979
Vancouver
Anonymous. Enhancement of Macular Pigment Density by Oral Lutein Supplementation. Insel Gruppe AG, University Hospital Bern. 2007.
BibTeX
@misc{anon2007Enhanc,
title = {Enhancement of Macular Pigment Density by Oral Lutein Supplementation},
author = {Anonymous},
journal = {Insel Gruppe AG, University Hospital Bern},
year = {2007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Insel Gruppe AG, University Hospital Bern 2018
Open access · US-GOV
FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment
PLoS ONE 2019
Open access · CC-BY
Effects of lutein supplementation in age-related macular degeneration
Nature reviews. Neuroscience 2014
Citation only
Blood-derived rejuvenation
Diseases (Basel, Switzerland) 2026
Open access · OA
Iontophoresis Drug Delivery to the Macula of Lutein for Age Related Macular Degeneration.
Journal of Drugs in Dermatology 2022
Open access · OA
A Narrative Review of Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside and Nicotinamide Mononucleotide for Keratinocyte Carcinoma Risk Reduction
The Eye Hospital of Wenzhou Medical University 2018
Open access · US-GOV